



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
12/497,728	07/06/2009	Francois Navarro	30731-USCNT3	7112
1095	7590	02/03/2010	EXAMINER	
NOVARTIS CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 EAST HANOVER, NJ 07936-1080			KIFLE, BRUCK	
			ART UNIT	PAPER NUMBER
			1624	
			MAIL DATE	DELIVERY MODE
			02/03/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
Response to Rule 312 Communication	12/497,728	NAVARRO ET AL.
	Examiner	Art Unit
	Bruck Kifle	1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. The amendment filed on 26 January 2010 under 37 CFR 1.312 has been considered, and has been:

- a) entered.
- b) entered as directed to matters of form not affecting the scope of the invention.
- c) disapproved because the amendment was filed after the payment of the issue fee.
Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.
- d) disapproved. See explanation below.
- e) entered in part. See explanation below.

New claim 3 is a duplicate of claim 1. Insertion of the language in page 4 which reads "together with one or more pharmaceutically acceptable diluent or carrier" would overcome the objection.

/Bruck Kifle/
Primary Examiner
Art Unit: 1624